Nature Communications (Jan 2022)
Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma
- Markus Schick,
- Le Zhang,
- Sabine Maurer,
- Hans Carlo Maurer,
- Konstandina Isaakaidis,
- Lara Schneider,
- Upayan Patra,
- Kathrin Schunck,
- Elena Rohleder,
- Julia Hofstetter,
- Apoorva Baluapuri,
- Anna Katharina Scherger,
- Julia Slotta-Huspenina,
- Franziska Hettler,
- Julia Weber,
- Thomas Engleitner,
- Roman Maresch,
- Jolanta Slawska,
- Richard Lewis,
- Rouzanna Istvanffy,
- Stefan Habringer,
- Katja Steiger,
- Armin Baiker,
- Robert A. J. Oostendorp,
- Cornelius Miething,
- Hans-Peter Lenhof,
- Florian Bassermann,
- Björn Chapuy,
- Matthias Wirth,
- Elmar Wolf,
- Roland Rad,
- Stefan Müller,
- Ulrich Keller
Affiliations
- Markus Schick
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Le Zhang
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Sabine Maurer
- Internal Medicine III, School of Medicine, Technische Universität München
- Hans Carlo Maurer
- Internal Medicine II, School of Medicine, Technische Universität München
- Konstandina Isaakaidis
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Lara Schneider
- Center for Bioinformatics, Saarland Informatics Campus, Saarland University
- Upayan Patra
- Institute of Biochemistry II, Goethe University, Medical School
- Kathrin Schunck
- Institute of Biochemistry II, Goethe University, Medical School
- Elena Rohleder
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Julia Hofstetter
- Cancer Systems Biology Group, Theodor Boveri Institute, University of Würzburg
- Apoorva Baluapuri
- Cancer Systems Biology Group, Theodor Boveri Institute, University of Würzburg
- Anna Katharina Scherger
- Internal Medicine III, School of Medicine, Technische Universität München
- Julia Slotta-Huspenina
- Institute of Pathology, School of Medicine, Technische Universität München
- Franziska Hettler
- Internal Medicine III, School of Medicine, Technische Universität München
- Julia Weber
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München
- Thomas Engleitner
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München
- Roman Maresch
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München
- Jolanta Slawska
- Internal Medicine III, School of Medicine, Technische Universität München
- Richard Lewis
- Internal Medicine III, School of Medicine, Technische Universität München
- Rouzanna Istvanffy
- Internal Medicine III, School of Medicine, Technische Universität München
- Stefan Habringer
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Katja Steiger
- Institute of Pathology, School of Medicine, Technische Universität München
- Armin Baiker
- Bavarian Health and Food Safety Authority
- Robert A. J. Oostendorp
- Internal Medicine III, School of Medicine, Technische Universität München
- Cornelius Miething
- Department of Hematology, Oncology, Stem Cell Transplantation, University Medical Center Freiburg
- Hans-Peter Lenhof
- Center for Bioinformatics, Saarland Informatics Campus, Saarland University
- Florian Bassermann
- Internal Medicine III, School of Medicine, Technische Universität München
- Björn Chapuy
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Matthias Wirth
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Elmar Wolf
- Cancer Systems Biology Group, Theodor Boveri Institute, University of Würzburg
- Roland Rad
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München
- Stefan Müller
- Institute of Biochemistry II, Goethe University, Medical School
- Ulrich Keller
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- DOI
- https://doi.org/10.1038/s41467-021-27704-8
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 16
Abstract
SUMOylation is a post-translational modification that has been shown to be altered in cancer. Here, the authors show that loss of the SUMO isopeptidase SENP6 leads to unrestricted SUMOylation and genomic instability promoting lymphomagenesis and generating vulnerability to PARP inhibition.
